Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TELA BioTELA +3.41%59 3-1 Month Momentum % is -25.08% as of Sep. 15, 2026. GuruFocus rates TELA with a GF Score™ of 59/100 and a GF Value™ of $1.41 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 841 Medical Devices & Instruments companies, TELA Bio ranks worse than 90.49% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-15), TELA Bio's 3-1 Month Momentum % is -25.08%.
The industry rank for TELA Bio's 3-1 Month Momentum % or its related term are showing as below:
TELA's 3-1 Month Momentum % is ranked worse than 90.49% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.43
vs TELA: -25.08
TELA Bio (NAS:TELA) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
TELA Bio 3-1 Month Momentum % Related Terms
TELA vs ARAY, MODD, NSYS: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, TELA Bio's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TELA Bio 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TELA Bio's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where TELA Bio's 3-1 Month Momentum % falls into.
TELA Bio (NAS:TELA) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELA Bio (TELA) has a 3-1 Month Momentum % of -25.08% as of Sep. 15, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on TELA Bio and its competitors. According to the industry distribution chart, TELA Bio ranks #761 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 90.5%.
Is TELA Bio's 3-1 Month Momentum % too high?
TELA Bio's current 3-1 Month Momentum % is -25.08%. Based on the distribution chart, TELA Bio ranks #761 out of 841 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TELA Bio has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TELA Bio's 3-1 Month Momentum % compare to ARAY and MODD?
According to the Medical Devices & Instruments industry distribution chart, TELA Bio ranks #761 out of 841 companies for 3-1 Month Momentum %. This places TELA Bio in the lower half of its industry. The industry median 3-1 Month Momentum % is 0.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
The median 3-1 Month Momentum % among Medical Devices & Instruments companies is 0.43, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on TELA Bio and its competitors. For the Medical Devices & Instruments industry, the median 3-1 Month Momentum % is 0.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TELA Bio's current 3-1 Month Momentum % is -25.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TELA Bio stock overvalued right now?
Based on GuruFocus' analysis, TELA Bio (TELA) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.41, compared to a current price of $1.06 — trading 24.8% below its estimated fair value. The current 3-1 Month Momentum % is -25.08%. TELA Bio's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For TELA Bio (TELA), the current 3-1 Month Momentum % is -25.08% as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TELA Bio (TELA) Overvalued in 2026?
Based on GuruFocus' analysis, TELA Bio stock appears to be undervalued.
The current stock price of $1.06 is trading 24.8% below its estimated GF Value™ of $1.41.
GuruFocus considers TELA Bio to be Modestly Undervalued.
Key valuation signals for TELA:
3-1 Month Momentum %: -25.08%
GF Value™: $1.41 vs. price of $1.06 (24.8% below fair value)
No single metric tells the full story. See the TELA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
59GF Score
Get the complete analysis for TELA
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELA has been successfully added to your 
